Lilly Quality Leader Walsh Appointed to Company's Executive Committee

INDIANAPOLIS, July 1, 2011 /PRNewswire/ -- Fionnuala Walsh, Ph.D., will join the executive committee of Eli Lilly and Company (NYSE: LLY) on July 1.

Walsh will continue in her current role as Lilly's senior vice president of global quality, reporting to John Lechleiter, Ph.D., chairman, president, and CEO, and working to ensure Lilly continues to maintain high quality standards across its worldwide operations.

Walsh is a recognized thought leader in the quality industry, often speaking about Lilly's sustainable, integrated quality system and the company's commitment to maintaining a quality culture. Her presence on the company's most senior governance committee is expected to further underscore Lilly's ongoing commitment to quality.

A native of Ireland, Walsh earned a bachelor's degree and doctoral degree in chemistry from University College Dublin. She joined Lilly's Kinsale, Ireland, manufacturing site in 1988 as a technical services chemist. After numerous positions there, she moved into a role as global quality leader at the Lilly Corporate Center in Indianapolis in 2002.

In January 2003, Walsh was named executive director of quality for U.S. drug product and Lilly Technology Center operations. In July 2005, she was named vice president of global quality operations, and, in June 2007, she was named senior vice president of global quality.

About Eli Lilly and Company

Lilly, a leading, innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers—through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.